Oxford Biomedica shares were down 0.4% to 649p in late morning trading on Wednesday after the company announced the appointment of Namrata P Patel as an independent non-executive director.
The gene and cell therapy firm confirmed Ms Patel’s appointment with immediate effect earlier today.
“Namrata is a high calibre and timely appointment for Oxford Biomedica as we advance our manufacturing and CMC capabilities, whilst expanding our global presence,” said Oxford Biomedia interim CEO Dr. Roch Doliveux.
“We warmly welcome her to the Board and look forward to utilising her international manufacturing and supply chain expertise, as well as her experience in sustainability as we deliver on our aim of becoming a global fully integrated viral vector leader.”
Oxford Biomedica highlighted Ms Patel’s previous work experience, such as her 25-year history with Procter and Gamble, including her current position as SVP, product supply at the group’s Global Beauty Sector.
The company further noted her selection of senior positions across multiple major global markets, and her key role as part of the team delivering on Procter and Gamble’s 2040 Sustainability Ambition Goals for its Beauty Business Portfolio.
Patel has also held senior positions at several multi-national companies including Gillete, WH Smith and Coca-Cola, with a particular focus on international supply chain management.
She holds a masters degree in Logistics and Management from the Cranfield School of Management, and a BA in Public Administration and Marketing from South Wales University.
“Oxford Biomedica is at an exciting time in its development as it broadens its scope into AAV and significantly expands its manufacturing capacity to meet the growing global demand for its viral vector capabilities,” said Patel.
“I look forward to working closely with the rest of the Board and the management team as the Company continues to progress as a global leader in the gene and cell therapy space.”